Zou X, et al. - Researchers intended to establish a screening method for pancreatic cancer (PC) patients by using serum microRNAs (miRNAs) in this study comprised of four phases: screening, training, testing, and external validation stage. A six-miRNA (let-7b-5p, miR-192-5p, miR-19a-3p, miR-19b-3p, miR-223-3p, and miR-25-3p) panel in serum was identified for early and noninvasive diagnosis of PC; 0.910 was the area under the receiver operating characteristic curves for the panel, and this was for the combined training and testing phases, which demonstrated higher diagnostic value vs the individual miRNA. A close association of increased serum miR-19a-3p with worse overall survival was revealed by prognostic value prediction using Cox's proportional hazards model and Kaplan-Meier curves.